Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business share buy-back

Zealand Pharma Share Buy-Back Program

Analysis based on 75 articles · First reported May 26, 2026 · Last updated Sep 21, 2026

Sentiment
30
Attention
4
Articles
75
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The share buy-back program by Zealand Pharma is generally viewed positively by the market as it can signal confidence from the company's management and potentially boost earnings per share, leading to increased investor interest. The increase in share capital by Zealand Pharma, while part of the overall program, could dilute existing shares if not offset by buy-backs, but in this context, it's part of a broader capital management strategy.

biotechnology pharmaceuticals

Zealand Pharma A/S, a biotechnology company, is conducting a share buy-back program initiated on May 7, 2026, and set to conclude by October 31, 2026. The program allows for repurchasing shares up to DKK 1.3 billion, with a maximum of 7,152,557 shares. Danske Bank has been appointed as the lead manager, making independent trading decisions. As of week 24 (June 8-12, 2026), Zealand Pharma holds 1,879,482 treasury shares, representing approximately 2.63% of its share capital. The company also increased its share capital by 53,183 new shares on June 8, 2026. The program adheres to EU Market Abuse Regulation and Safe Harbour Regulation.

67 Zealand Pharma initiates share buy-back
60 Zealand Pharma repurchased shares
55 Zealand Pharma repurchased shares
35 Zealand Pharma appointed lead manager Danske Bank
30 Danske Bank executed buy-back transactions Zealand Pharma
stock
Zealand Pharma is the issuer conducting the buy-back, repurchasing its own shares to return capital and reduce share count. The program signals balance-sheet confidence but is routine and already anticipated by the market.
Importance 100.0 Sentiment 5.0
stock
Danske Bank serves as lead manager executing the buy-back transactions independently on behalf of Zealand Pharma. The role is a routine mandate with minimal financial or reputational effect.
Importance 40.0 Sentiment 1.0
exch
Nasdaq Copenhagen is the exchange where all buy-back transactions were executed. The activity adds modest trading volume but has no material effect on the venue.
Importance 20.0 Sentiment 0.0
curr
The Denmark — Danish krone is the currency in which the buy-back consideration and share prices are denominated. The program's scale is too small to affect the currency.
Importance 15.0 Sentiment 0.0
exch
Nasdaq is the listing venue for Zealand Pharma's American Depositary Receipts under ticker ZEAL. The buy-back has only an indirect, negligible effect on the exchange.
Importance 10.0 Sentiment 0.0
cnt
Denmark is the home jurisdiction and headquarters location of Zealand Pharma, whose buy-back complies with EU and Danish regulations. The event has no material impact on the country.
Importance 10.0 Sentiment 0.0
alliance
The share buy-back program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, 'MAR') and Commission Delegated Regulation (EU) 2016/1052 (the 'Safe Harbour Regulation').
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.